Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

GSK - Doublet: A Phase I Study of Pegylated Liposomal Doxorubicin (Doxil) and Weekly Intravenous Topotecan in Patients With Advanced Solid Tumors

NCT00252889 is registered in ClinicalTrials.gov with Christiana Care Health Services as lead sponsor.

NCT NCT00252889
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00252889 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
GSK - Doublet: A Phase I Study of Pegylated Liposomal Doxorubicin (Doxil) and Weekly Intravenous Topotecan in Patients With Advanced Solid Tumors
Lead sponsor
Christiana Care Health Services
Phase
Phase 1
Overall status
Completed
Start date
May 31, 2004
Completion date
June 30, 2008
Enrollment
20 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

esophageal cancer, gastric cancer, head and neck cancer, pancreatic cancer, small cell lung cancer